EE448 The Economic Impact of Polatuzumab Vedotin as First-Line Therapy for High-Risk DLBCL on Subsequent Treatments Within the Italian National Health Service
Abstract
Authors
M Bellone L Castello D Ghislieri
M Bellone L Castello D Ghislieri
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now